Axsome Therapeutics Inc (AXSM)vsModerna Inc (MRNA)
AXSM
Axsome Therapeutics Inc
$220.75
+4.56%
HEALTHCARE · Cap: $10.89B
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 187% more annual revenue ($2.23B vs $776.57M). AXSM leads profitability with a -24.7% profit margin vs -141.4%. AXSM earns a higher WallStSmart Score of 31/100 (F).
AXSM
Avoid31
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.6%
Fair Value
$385.01
Current Price
$220.75
$164.26 discount
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 45.5% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Trading at 138.8x book value
ROE of -345.0% — below average capital efficiency
Negative free cash flow — burning cash
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AXSM
The strongest argument for AXSM centers on Revenue Growth. Revenue growth of 45.5% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : AXSM
The primary concerns for AXSM are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 2.63 is elevated, increasing financial risk.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
AXSM profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
AXSM is growing revenue faster at 45.5% — sustainability is the question.
AXSM generates stronger free cash flow (-33M), providing more financial flexibility.
Bottom Line
AXSM scores higher overall (31/100 vs 21/100) and 45.5% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Axsome Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?